Activating mutations in the ESR1 gene are a known mechanism of secondary resistance to endocrine therapy in metastatic estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancers. This evidence concerns the gene ESR1 and breast cancer.